Research advances in antiviral drugs for the treatment of hepatitis D virus infection
- VernacularTitle:丁型肝炎病毒治疗药物的研究进展
- Author:
Yang LIU
1
;
Yonghe QI
1
;
Zhongmin ZHOU
1
;
Jianhua SUI
1
;
Wenhui LI
2
Author Information
- Publication Type:Journal Article
- Keywords: Hepatitis Delta Virus; Antiviral Agents; Bulevirtide; Libevitug
- From: Journal of Clinical Hepatology 2026;42(2):278-285
- CountryChina
- Language:Chinese
- Abstract: Co-infection of hepatitis D virus （HDV） and hepatitis B virus （HBV） is the most severe form of viral hepatitis and is associated with accelerated progression of liver disease and a significant increase in the risk of liver cirrhosis and hepatocellular carcinoma. Nucleo（s）tide analogues for HBV treatment are ineffective against HDV infection， necessitating the urgent need for developing specific and effective antiviral therapies for HDV. In recent years， significant advances have been made in the research and development of specific antiviral drugs against HDV， including entry inhibitors targeting viral entry （Bulevirtide） and monoclonal antibody drugs （Libevitug）， which bring ground-breaking advances in the treatment of HDV infection. This article briefly reviews the latest research advances in therapeutic drugs for HDV， introduces the mechanism of action and clinical research data of new drugs recently approved for the treatment of HDV， and discusses the challenges that need to be solved in the field of HDV treatment， in order to provide a reference for understanding the current status of hepatitis D treatment.
